- Title: Subtitle
- Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma
- Creators
- Igor Puzanov - Vanderbilt UniversityMohammed M. Milhem - University of IowaRobert Hans Ingemar Andtbacka - Huntsman Cancer InstituteDavid R. Minor - Northern California Melanoma CenterOmid Hamid - Angeles Clinic and Research InstituteAi Li - AmgenMichael Chastain - AmgenKevin Gorski - AmgenAbraham Anderson - AmgenAri M. Vanderwalde - AmgenJeffrey Chou - AmgenHoward Kaufman - Rush University Medical Center
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.32(15_suppl), pp.9029-9029
- DOI
- 10.1200/jco.2014.32.15_suppl.9029
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2014
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984363173502771
Abstract
Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma
Journal of clinical oncology, Vol.32(15_suppl), pp.9029-9029
05/20/2014
DOI: 10.1200/jco.2014.32.15_suppl.9029
Details
Metrics
14 Record Views